+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 56 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
T

Actively Recruiting

Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.

Age: 18Years +All GendersPhase 2
125 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.

Age: 18Years - 80YearsAll GendersPhase 2
114 locations
P

Actively Recruiting

Researchers are evaluating the effects of different doses of brivekimig compared to a placebo in adults with moderate to severe Crohns disease. This phase 2, randomized, double-blind study aims to assess the treatments impact on endoscopic response and remission. The trial includes participants who have not adequately responded to standard therapies. The study is sponsored by Sanofi and plans to enroll adults aged 18 to 75 years. Participants will be randomly assigned to receive one of two dosing regimens of brivekimig or a placebo, all administered by subcutaneous injection. The treatment period can last up to 158 weeks and includes an optional open-label long-term extension lasting up to 104 weeks for eligible participants. The study design includes three groups two experimental brivekimig dose regimens and one placebo group. Throughout the study, participants will undergo assessments to measure endoscopic response at week 16 and other clinical outcomes such as remission rates, symptom scores, serum drug levels, and safety monitoring for adverse events. Evaluations include Crohns Disease Activity Index scores, patient-reported outcomes, and endoscopic examinations up to week 52. The total duration of participation may be up to 168 weeks, with ongoing safety and efficacy monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
78 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
E

Actively Recruiting

Researchers are studying the safety and effectiveness of a minimally invasive device called the Alleviant ALV1 System in patients with chronic heart failure, specifically those with heart failure with preserved or mildly reduced ejection fraction HFpEFHFmrEF. This prospective, multicenter, randomized, double-blind trial compares the device procedure to a sham control in order to better understand its potential benefits and risks. Participants are randomly assigned to one of two groups. Those in the treatment group undergo cardiac imaging, femoral vein access, and receive the Alleviant ALV1 System device procedure, which creates an interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement without the device procedure. The study has a crossover design, allowing participants to experience both conditions during the trial. During the study, participants will have cardiac imaging and exercise right heart catheterization to monitor heart function and pressures. Researchers will evaluate a composite primary endpoint at 12 months to assess safety and efficacy. Participants will be monitored for ongoing health status while continuing stable guideline-directed medical therapy. The trial is expected to complete by December 2032.

Age: 40Years +All GendersPhase Not Applicable
93 locations

1-10 of 56

1